CDK4 and neoplasm: Indeed, recent studies in ER-positive breast cancer models demonstrated that low doses of novel FOXM1 inhibitors acted synergistically with low doses of CDK4/6 inhibitors (abemaciclib, palbociclib, or ribociclib) to efficiently suppress tumor cell growth [134].